Bicocca Open Archive

Logo unimib boa
CAZZANIGA, MARINA ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.211
AS - Asia 7.917
EU - Europa 7.500
SA - Sud America 1.171
AF - Africa 204
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 7
Totale 27.022
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.977
SG - Singapore 2.997
SE - Svezia 2.358
IT - Italia 1.614
CN - Cina 1.361
HK - Hong Kong 1.195
VN - Vietnam 1.074
RU - Federazione Russa 925
BR - Brasile 864
DE - Germania 784
IE - Irlanda 518
FR - Francia 253
GB - Regno Unito 240
IN - India 233
ID - Indonesia 187
UA - Ucraina 154
FI - Finlandia 142
BD - Bangladesh 133
CA - Canada 133
AT - Austria 121
AR - Argentina 117
KR - Corea 117
IQ - Iraq 88
TR - Turchia 88
NL - Olanda 83
ES - Italia 77
PK - Pakistan 73
JP - Giappone 62
MX - Messico 61
ZA - Sudafrica 61
PH - Filippine 57
DK - Danimarca 54
SA - Arabia Saudita 47
EC - Ecuador 42
CO - Colombia 41
PL - Polonia 37
CH - Svizzera 36
VE - Venezuela 33
UZ - Uzbekistan 31
CL - Cile 28
JO - Giordania 26
KE - Kenya 26
MA - Marocco 26
TN - Tunisia 19
LT - Lituania 17
PS - Palestinian Territory 17
BE - Belgio 16
PY - Paraguay 16
EG - Egitto 15
AE - Emirati Arabi Uniti 13
AL - Albania 13
RO - Romania 13
MY - Malesia 12
TH - Thailandia 12
UY - Uruguay 12
DZ - Algeria 11
JM - Giamaica 11
ET - Etiopia 10
KZ - Kazakistan 10
AU - Australia 9
AZ - Azerbaigian 9
BO - Bolivia 9
IR - Iran 9
NP - Nepal 9
CR - Costa Rica 8
CZ - Repubblica Ceca 8
IL - Israele 8
LB - Libano 8
OM - Oman 8
PE - Perù 8
TW - Taiwan 7
CI - Costa d'Avorio 6
AM - Armenia 5
HN - Honduras 5
NG - Nigeria 5
PT - Portogallo 5
SC - Seychelles 5
BG - Bulgaria 4
BY - Bielorussia 4
EU - Europa 4
SK - Slovacchia (Repubblica Slovacca) 4
AO - Angola 3
BH - Bahrain 3
CY - Cipro 3
DO - Repubblica Dominicana 3
LY - Libia 3
MN - Mongolia 3
MT - Malta 3
MU - Mauritius 3
PA - Panama 3
SN - Senegal 3
SY - Repubblica araba siriana 3
A1 - Anonimo 2
BA - Bosnia-Erzegovina 2
BW - Botswana 2
GR - Grecia 2
GT - Guatemala 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
Totale 26.987
Salva come PNG Salva come JPEG
Città #
Stockholm 1.887
Singapore 1.764
Ann Arbor 1.733
Hong Kong 1.164
Ashburn 897
San Jose 729
Frankfurt am Main 509
Fairfield 506
Dublin 505
Milan 495
Chandler 367
Wilmington 352
New York 332
Woodbridge 305
Ho Chi Minh City 290
Hanoi 283
Houston 259
Santa Clara 256
Chicago 245
Dallas 232
Hefei 209
Los Angeles 204
Seattle 203
The Dalles 186
Cambridge 183
Beijing 172
Princeton 160
Jakarta 153
Lauterbourg 136
Jacksonville 113
Seoul 105
Council Bluffs 104
Dearborn 86
Moscow 84
Helsinki 79
Vienna 78
Lawrence 74
Altamura 72
São Paulo 71
Buffalo 70
Shanghai 69
London 61
Munich 56
San Diego 55
Rome 53
Haiphong 52
Tokyo 50
Nuremberg 49
Guangzhou 46
Boardman 40
Da Nang 39
Montreal 39
Rio de Janeiro 39
Orem 38
Baghdad 37
Nanjing 36
Andover 33
Desio 33
Zurich 33
Lappeenranta 31
Brooklyn 29
Mumbai 29
Atlanta 28
Denver 28
Salt Lake City 28
Toronto 28
Dong Ket 27
Warsaw 27
Tashkent 26
Chennai 25
Hải Dương 24
Amman 23
Phoenix 23
Johannesburg 22
Lissone 22
Monza 22
Pune 22
Changsha 21
Falls Church 21
Kent 21
Lahore 21
Nairobi 21
Amsterdam 20
Dhaka 20
Poplar 20
Paris 19
Belo Horizonte 18
Jeddah 18
Riyadh 18
Tianjin 18
Ha Long 17
Kocaeli 17
San Francisco 17
Tampa 17
Turku 17
Zhengzhou 17
Brasília 16
Buenos Aires 16
Curitiba 16
Florence 16
Totale 17.396
Salva come PNG Salva come JPEG
Nome #
Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial 1.942
Methotrexate inhibits SARS-CoV-2 virus replication "in vitro" 559
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 445
A Multidisciplinary Intervention to Tell Children about the Parent's Cancer: Preliminary Results 432
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 421
Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection 386
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 383
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 378
Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study 369
A second update on mapping the human genetic architecture of COVID-19 361
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 360
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 348
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study 342
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 340
Mapping the human genetic architecture of COVID-19 333
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 327
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 319
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 304
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer 303
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 301
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 300
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 283
The antiangiogenic effect of the metronomic combination of 5-Fluorouracil plus vinorelbine is mediated by FAK/AKT pathway downregulation and apoptosis activation 282
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 282
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 280
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study 278
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 268
A multidisciplinary approach to screen the post-COVID-19 conditions 260
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 259
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 254
Neurofilament light chain serum levels as a possible paclitaxel-induced peripheral neurotoxicity biomarker: pilot and feasibility study. 246
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 244
Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract 244
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 239
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 239
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 237
Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation 235
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 234
When progressive dysphagia could be related to an “old friend” – a case report 232
Auto-antibodies against type I IFNs in patients with life-threatening COVID-19 229
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 226
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 213
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 211
Correction: NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (Breast Cancer Research (2019) 21 (133) DOI: 10.1186/s13058-019-1196-y) 208
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study 208
Stratified analyses refine association between TLR7 rare variants and severe COVID-19 207
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 207
How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story 204
Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874) 201
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study 200
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows 196
Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic 195
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success 187
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 187
Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer 185
The role for tocilizumab in covid-19 patients: Reflections on monza cohort data 184
A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial 183
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 181
Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874) 181
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 177
NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer 174
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 174
A possible biomarker for paclitaxel-induced peripheral neurotoxicity: Neurofilament light chain serum levels monitoring 172
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 172
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 171
Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study 169
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 169
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy 167
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 167
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients 166
Metronomic chemotherapy 166
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study 166
Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project 161
Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE 157
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 157
Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future? 157
Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project 156
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study 154
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 153
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 150
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) 148
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 148
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer 147
Adjuvant systemic treatment of early breast cancer: the NORA study 143
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 142
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 141
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study 136
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience 135
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now? 133
Targeted therapies for the treatment of breast cancer in the post-trastuzumab era 133
Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study 132
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) [Trattamento con Gefitinib nei pazienti anziani o con scarso performance status (PS), affetti da carcinoma polmonare non a piccole cellule (NSCLC)] 131
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 131
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 128
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study 128
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial 124
Gene expression profiling in breast cancer: a clinical perspective 123
Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers 122
Biological characteristics and medical treatment of breast cancer in young women-a featured population: results from the NORA study 118
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: A multi-cycle, phase II study 118
Totale 23.958
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.638
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.638
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021366 0 0 0 0 0 0 0 0 0 0 175 191
2021/20221.198 126 121 150 87 49 90 62 89 58 75 85 206
2022/20232.106 252 550 162 154 121 268 135 140 100 62 87 75
2023/20241.945 89 75 67 93 255 397 354 57 171 56 65 266
2024/20255.336 260 748 412 263 373 265 308 171 561 765 387 823
2025/202612.418 1.320 845 839 1.182 1.282 574 1.748 651 1.082 2.882 13 0
Totale 27.795